news

news

Corporate News

PARTICIPATION AT CHINABIO® PARTNERING FORUM
  • 2024-09-11
  • 561

 

Hudson Therapeutics Seeks Strategic Partners and Institutional Investors at ChinaBio® Partnering Forum September 2024

 

[Cambridge, MA / Research Triangle Park, NC / Seoul, Korea – Sep 3, 2024] Hudson Therapeutics, Incorporated a leading innovator in therapeutic solutions and a US subsidiary of Shaperon, Incorporated is pleased to announce its participation in the upcoming Bio China Partnering Forum 2024. The partnering event is September 10th to 11th in Shanghai China, bringing together global industry leaders, investors, and innovators in the biotechnology and pharmaceuticals sectors.

At the conference, Hudson Therapeutics and Shaperon will actively seek strategic partners to out-license and meet investors to expand its footprint in the Chinese market. With a robust pipeline of innovative therapeutic candidates, the company aims to leverage this platform to establish key partnerships that will drive the development and commercialization of its innovative products in China.

“Our participation in Bio China Partnering Forum 2024 represents a significant step in our strategic plan to expand into the Chinese market,” said Janice Marie McCourt, CEO of Hudson Therapeutics. “We are eager to engage with potential partners and investors who share our vision of advancing healthcare through innovative therapeutics. This forum offers a unique opportunity to collaborate with leading companies and investors in China, and we look forward to exploring mutually beneficial partnerships.”

Hudson Therapeutics and Shaperon’s Global Business Development Team will lead meetings with global pharmaceutical partners and new potential collaborators to discuss technology transfer of NuGel – Atopic Dermatitis Treatment in Phase 2B clinical trials in the US, Nucerin – Alzheimer Disease Treatment in Phase 1 clinical trials in Korea and Papiliximab – dual-target Nanobody Antibody that was highlighted at the American Association for Cancer Research (AACR) in April., along with additional preclinical programs in ulcerative colitis, Crohn’s Disease, MASH, and obesity along with additional opportunities in veterinary medicine focused in companion animals.